EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs

Nikol A Zografou-Barredo, Alex J Hallatt, Jennyfer Goujon-Ricci, Céline Cano

Bioorganic & Medicinal Chemistry · 2023-06 · 88-89 · 117334

DOI: 10.1016/j.bmc.2023.117334 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic & Medicinal Chemistry, 2023-06. Verfasst von Nikol A Zografou-Barredo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, School of Natural and Environmental Sciences, Newcastle Uni…. Hauptthemen laut MEDLINE: Proteins, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the last two decades, proteolysis targeting chimeras (PROTACs) have been revolutionary in drug development rendering targeted protein degradation (TPD) as an emerging therapeutic modality. These heterobifunctional molecules are comprised of three units: a ligand for the protein of interest (POI), a ligand for an E3 ubiquitin ligase, and a linker that tethers the two motifs together. Von Hippel-Lindau (VHL) is one of the most widely employed E3 ligases in PROTACs development due to its prevalent expression across tissue types and well-characterised ligands. Linker composition and length has proven to play an important role in determining the physicochemical properties and spatial orientation of the POI-PROTAC-E3 ternary complex, thus influencing the bioactivity of degraders. Numerous articles and reports have been published showcasing the medicinal chemistry aspects of the linker design, but few have focused on the chemistry around tethering linkers to E3 ligase ligands. In this review, we focus on the current synthetic linker strategies employed in the assembly of VHL-recruiting PROTACs. We aim to cover a range of fundamental chemistries used to incorporate linkers of varying length, composition and functionality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteinsUbiquitin-Protein LigasesLigandsProteolysisVon Hippel-Lindau Tumor Suppressor Protein

Stichwörter der Autor:innen

DegradersE3 ubiquitin ligaseLinker connectivityLinkerologyPROTACsTargeted protein degradation (TPD)Ternary complexVon Hippel-Lindau (VHL)

Substanzen

LigandsProteinsUbiquitin-Protein LigasesVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Autor:innen und Institutionen

  • Cancer Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Cancer Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, UK. Electronic address: celine.cano@newc…

Förderung

  • Cancer Research UK

Zitieren

APA

Zografou-Barredo, N. A., Hallatt, A. J., Goujon-Ricci, J., & Cano, C. (2023). A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs. Bioorganic & Medicinal Chemistry, 88-89, 117334. https://doi.org/10.1016/j.bmc.2023.117334

Vancouver

Zografou-Barredo NA, Hallatt AJ, Goujon-Ricci J, Cano C. A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs. Bioorganic & Medicinal Chemistry. 2023;88-89:117334. doi:10.1016/j.bmc.2023.117334

BibTeX
@article{ZografouBarredo2023,
  author = {Zografou-Barredo, Nikol A and Hallatt, Alex J and Goujon-Ricci, Jennyfer and Cano, Céline},
  title = {A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2023},
  volume = {88-89},
  pages = {117334},
  doi = {10.1016/j.bmc.2023.117334}
}
Kostenlos starten →